Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00292370 · ClinicalTrials.gov registry record · Phase 4
Quetiapine Augmentation for Treatment-resistant PTSD
A Phase 4 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 4
- Development phase
- 124
- Enrollment target
NCT00292370: Completed Phase 4 study, sponsored by VA Office of Research and Development.
NCT00292370 is a Phase 4 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 124 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00292370, a Phase 4 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 124 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the response of veterans with PTSD without an optimal response to paroxetine to quetiapine augmentation versus placebo.
Interventions
- DRUG Placebo
- DRUG Quetiapine
- DRUG Open Label (OL) Paroxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2006-01 |
| Est. Completion | 2009-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00292370
The ClinicalTrials.gov registry entry for NCT00292370 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00292370 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00292370 about?
NCT00292370 is a clinical study titled "Quetiapine Augmentation for Treatment-resistant PTSD". The purpose of this study is to compare the response of veterans with PTSD without an optimal response to paroxetine to quetiapine augmentation versus placebo.
What is the current status of trial NCT00292370?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 124 participants. The study started on 2006-01. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00292370?
The interventions under investigation include: Placebo (DRUG), Quetiapine (DRUG), Open Label (OL) Paroxetine (DRUG).
Who is sponsoring clinical trial NCT00292370?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.